The Effect of Engineered Mannitol-lactose Mixture on Dry Powder Inhaler Performance

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2012 Apr 6

PMID 22477070

Citations 9

Authors

Waseem Kaialy

Hassan Larhrib

Gary P Martin

Ali Nokhodchi

Affiliations

Soon will be listed here.

Abstract

Purpose: To co-crystallise mannitol and lactose with a view to obtaining crystals with more favourable morphological features than either lactose or mannitol alone, suitable for use as carriers in formulations for dry powder inhalers (DPIs) using simultaneous engineering of lactose-mannitol mixtures.

Methods: Mannitol and lactose individually and the two sugars with three different ratios were crystallised/co-crystallised using anti-solvent precipitation technique. Obtained crystals were sieved to separate 63-90 μm size fractions and then characterised by size, shape, density and in vitro aerosolisation performance. Solid state of crystallized samples was studied using FT-IR, XRPD and DSC.

Results: At unequal ratios of mannitol to lactose, the elongated shape dominated in the crystallisation process. However, lactose exerted an opposite effect to that of mannitol by reducing elongation ratio and increasing the crystals' width and thickness. Crystallised β-lactose showed different anomers compared to commercial lactose (α-lactose monohydrate). Crystallised α-mannitol showed different polymorphic form compared to commercial mannitol (β-mannitol). Crystallised mannitol:lactose showed up to 5 transitions corresponding to α-mannitol, α-lactose monohydrate, β-lactose, 5α-/3β-lactose and 4α-/1β-lactose. In vitro deposition assessments showed that crystallised carriers produced more efficient delivery of salbutamol sulphate compared to formulations containing commercial grade carriers.

Conclusion: The simultaneous crystallization of lactose-mannitol can be used as a new approach to improve the performance of DPI formulations.

Citing Articles

Enhancing bioavailability of natural extracts for nutritional applications through dry powder inhalers (DPI) spray drying: technological advancements and future directions.

Wang B, Xiang J, He B, Tan S, Zhou W Front Nutr. 2023; 10:1190912.

PMID: 37476406 PMC: 10354342. DOI: 10.3389/fnut.2023.1190912.

Carrier-Free Inhalable Dry Microparticles of Celecoxib: Use of the Electrospraying Technique.

Jahangiri A, Nokhodchi A, Asare-Addo K, Salehzadeh E, Emami S, Yaqoubi S Biomedicines. 2023; 11(6).

PMID: 37371841 PMC: 10296448. DOI: 10.3390/biomedicines11061747.

Imagine the Superiority of Dry Powder Inhalers from Carrier Engineering.

Mehta P J Drug Deliv. 2018; 2018:5635010.

PMID: 29568652 PMC: 5820590. DOI: 10.1155/2018/5635010.

Nanocomposite microparticles (nCmP) for the delivery of tacrolimus in the treatment of pulmonary arterial hypertension.

Wang Z, Cuddigan J, Gupta S, Meenach S Int J Pharm. 2016; 512(1):305-313.

PMID: 27568494 PMC: 5030191. DOI: 10.1016/j.ijpharm.2016.08.047.

Synthesis and Characterization of Nanocomposite Microparticles (nCmP) for the Treatment of Cystic Fibrosis-Related Infections.

Wang Z, Meenach S Pharm Res. 2016; 33(8):1862-72.

PMID: 27091030 PMC: 4945441. DOI: 10.1007/s11095-016-1921-5.

References

Kaialy W, Alhalaweh A, Velaga S, Nokhodchi A . Effect of carrier particle shape on dry powder inhaler performance. Int J Pharm. 2011; 421(1):12-23. DOI: 10.1016/j.ijpharm.2011.09.010. View

Shah S, Misra A . Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance. AAPS PharmSciTech. 2005; 5(4):e65. PMC: 2750490. DOI: 10.1208/pt050465. View

Jones M, Harris H, Hooton J, Shur J, King G, Mathoulin C . An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances. Eur J Pharm Biopharm. 2008; 69(2):496-507. DOI: 10.1016/j.ejpb.2007.11.019. View

Haque M, Roos Y . Crystallization and X-ray diffraction of spray-dried and freeze-dried amorphous lactose. Carbohydr Res. 2005; 340(2):293-301. DOI: 10.1016/j.carres.2004.11.026. View

Shah K, Hussain M, Hubert M, Farag Badawy S . Form conversion of anhydrous lactose during wet granulation and its effect on compactibility. Int J Pharm. 2008; 357(1-2):228-34. DOI: 10.1016/j.ijpharm.2008.02.008. View

Fanni J, Parmentier M . Physical and chemical properties of molecular compounds of lactose. J Dairy Sci. 2000; 82(12):2558-63. DOI: 10.3168/jds.S0022-0302(99)75510-4. View

Kaialy W, Martin G, Larhrib H, Ticehurst M, Kolosionek E, Nokhodchi A . The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers. Colloids Surf B Biointerfaces. 2011; 89:29-39. DOI: 10.1016/j.colsurfb.2011.08.019. View

Kaialy W, Martin G, Ticehurst M, Royall P, Mohammad M, Murphy J . Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers. AAPS J. 2010; 13(1):30-43. PMC: 3032097. DOI: 10.1208/s12248-010-9241-x. View

Shur J, Harris H, Jones M, Kaerger J, Price R . The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations. Pharm Res. 2008; 25(7):1631-40. DOI: 10.1007/s11095-008-9538-y. View

10.

Kaialy W, Ticehurst M, Murphy J, Nokhodchi A . Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone. J Pharm Sci. 2011; 100(7):2665-84. DOI: 10.1002/jps.22483. View

11.

Dickhoff B, de Boer A, Lambregts D, Frijlink H . The effect of carrier surface and bulk properties on drug particle detachment from crystalline lactose carrier particles during inhalation, as function of carrier payload and mixing time. Eur J Pharm Biopharm. 2003; 56(2):291-302. DOI: 10.1016/s0939-6411(03)00109-7. View

12.

Coates M, Fletcher D, Chan H, Raper J . Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length. J Pharm Sci. 2004; 93(11):2863-76. DOI: 10.1002/jps.20201. View

13.

Jouppila K, Kansikas J, Roos Y . Crystallization and X-ray diffraction of crystals formed in water-plasticized amorphous lactose. Biotechnol Prog. 1998; 14(2):347-50. DOI: 10.1021/bp980010s. View

14.

Kirk J, Dann S, Blatchford C . Lactose: a definitive guide to polymorph determination. Int J Pharm. 2006; 334(1-2):103-14. DOI: 10.1016/j.ijpharm.2006.10.026. View

15.

Ooi J, Traini D, Hoe S, Wong W, Young P . Does carrier size matter? A fundamental study of drug aerosolisation from carrier based dry powder inhalation systems. Int J Pharm. 2011; 413(1-2):1-9. DOI: 10.1016/j.ijpharm.2011.04.002. View

16.

Kaialy W, Momin M, Ticehurst M, Murphy J, Nokhodchi A . Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler. Colloids Surf B Biointerfaces. 2010; 79(2):345-56. DOI: 10.1016/j.colsurfb.2010.04.016. View

17.

Guenette E, Barrett A, Kraus D, Brody R, Harding L, Magee G . Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design. Int J Pharm. 2009; 380(1-2):80-8. DOI: 10.1016/j.ijpharm.2009.07.002. View

18.

Burger A, Henck J, Hetz S, Rollinger J, Weissnicht A, Stottner H . Energy/temperature diagram and compression behavior of the polymorphs of D-mannitol. J Pharm Sci. 2000; 89(4):457-68. DOI: 10.1002/(SICI)1520-6017(200004)89:4<457::AID-JPS3>3.0.CO;2-G. View

19.

Kaialy W, Ticehurst M, Nokhodchi A . Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate. Int J Pharm. 2011; 423(2):184-94. DOI: 10.1016/j.ijpharm.2011.12.018. View

20.

Anderson P . Delivery options and devices for aerosolized therapeutics. Chest. 2001; 120(3 Suppl):89S-93S. DOI: 10.1378/chest.120.3_suppl.89s. View